Reprint

New Insights into Molecular Mechanisms Underlying Neurodegenerative Disorders

Edited by
October 2022
194 pages
  • ISBN978-3-0365-5486-0 (Hardback)
  • ISBN978-3-0365-5485-3 (PDF)

This book is a reprint of the Special Issue New Insights into Molecular Mechanisms Underlying Neurodegenerative Disorders that was published in

Biology & Life Sciences
Computer Science & Mathematics
Medicine & Pharmacology
Public Health & Healthcare
Summary

Neurodegenerative disorders encompass a broad range of sporadic and/or familial debilitating conditions characterized by the progressive dysfunction and loss of selective neuronal populations, determining different clinical phenotypes. Emerging research data indicate an interplay of genetic factors and epigenetic mechanisms underlying neurodegenerative processes, which lead to increased prevalence of neurodegenerative disorders. In concert with the constant increase in the aging population, neurodegenerative disorders currently represent a major challenge to public health worldwide. Despite recent advances in clinical and preclinical research, the pathogenesis of these disorders still remains poorly understood, without effective treatments being available to halt the neurodegenerative processes, but rather aiming at relieving symptoms. Therefore, a critical evaluation of current research data and in-depth understanding of the molecular mechanisms that lead to neurodegeneration are crucial in order to identify potential therapeutic targets that can pave the way to the development of novel and promising therapies. This Special Issue is focused on novel molecular data in the field of neurodegeneration that associate with the onset and progression of neurodegenerative diseases. We are particularly interested in original articles and reviews that provide new insights into the main molecular pathogenic mechanisms underlying neurodegenerative disorders, aiming to identify potential biomarkers and novel therapeutic strategies.

Format
  • Hardback
License
© 2022 by the authors; CC BY-NC-ND license
Keywords
Parkinson’s disease; schizophrenia; Mendelian randomization; genetics; TLRs; neuroinflammation; neuroprotection; neurodegeneration Parkinson’s disease; Alzheimer’s disease; Alzheimer’s disease; aducanumab; LMICs; APOE; burden of disease; treatment cost; Parkinson disease; epigenetics; DNA methylation; histone modifications; lcRNAs; environmental toxins; smoking; pesticides; coffee; diagnosis; stochasticity; space-time; entropy; neurodegeneration; EEG; MEG; graph theory; Alzheimer; Parkinson; Interleukin-37; central nervous system diseases; inflammatory; anti-inflammatory; cytokines; Parkinson’s disease; gut microbiota; gut–brain axis; dysbiosis; homology modelling; LOMETS; MUSTER; iGEMDOCK; AutoDock vina; Parkinson’s disease; MPTP model; mice; tyrosine hydroxylase; phosphorylation; neurodegeneration; neuroplasticity; Alzheimer’s disease viral hypothesis; human herpesviruses; amyloid beta (Aβ); tau protein; neuroinflammation; n/a; Parkinson’s disease; levodopa-induced dyskinesia; circular RNA; next-generation sequencing